Business
May 4, 2026
Taipei, Taiwan, 4 May 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced the successful global launch of its Nintedanib soft gel capsules (100mg and 150m...
Investors
Apr 10, 2026
Taipei, Taiwan, 10 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for March 2026 of NT$4,354 million, represent...
Business
Apr 8, 2026
Taipei, Taiwan, 08 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical company headquartered in Taiwan, today announced that Zepzelca® (lurbinectedin), its licensed oncology product, has receiv...
Business
Apr 2, 2026
Taipei, Taiwan, 02 April 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a leading global pharmaceutical company, today announced that it has entered into an agreement to acquire Sandoz AG’s Philippines business. Subj...
Investors
Mar 12, 2026
Taipei, Taiwan, 12 March 2026 — Lotus Pharmaceuticals (1795:TT; “Lotus” or “the Company”), a multinational pharmaceutical company, announced its audited financial results for the full year 2025, delivering the seventh co...
Investors
Mar 10, 2026
Taipei, Taiwan, 10 March 2026 — Lotus Pharmaceutical Co., Ltd. (Taiwan Stock Exchange: 1795), a global pharmaceutical leader based in Taiwan, today announced its unaudited consolidated revenues for February 2026 of NT$2,238 million, repres...
